FDA approves Imaavy as the first treatment for warm autoimmune hemolytic anemia, McKesson agrees to acquire Precision ...

Komodo Health built this framework from its deployments at Genmab and Ipsen, identifying three components that separate AI ...

Medicare Advantage has become a tougher business just as Costco is preparing to enter it. That apparent contradiction is what makes Costco’s partnership with SCAN Group worth wa ...

K2 Therapeutics CEO Ying Huang on the drug development pipeline — and the compounding attrition rates that make FDA approval ...

Evolving global expectations for CGT validation, comparability, and supply continuity elevate the need for operational and ...

McKesson will place Precision Medicine Group within Oncology & Multispecialty, aiming to strengthen trial execution and broaden end-to-end services spanning development, market access, and ...

FDA approved Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia in adults and pediatric patients ...

Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most ...

Mechanistically, HM17321 is a Ucn2 analog enabling a non-GLP-1 approach aimed at improving body composition by selectively reducing adiposity while preserving muscle mass and function. Preclinical ...

LaValle has worked with elite sports teams, military, and first responders, optimizing performance and recovery. He has authored 26 books, including Cracking the Metabolic Code, and over 200 articles.

Bristol Myers Squibb and Hengrui Pharma launch a multibillion-dollar collaboration spanning 13 oncology, hematology, and immunology programs to expand global drug development pipelines and accelerate ...

Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...